Skip to main content

Table 1 Baseline characteristics of each study compared to the validation study

From: The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer

StudyNumber of patientsMean age% MaleStage of diseaseUtility - Mean (SD) [range]
AURA 220363.031.0I/II 10%
III 14%
IV 75%
0.789 (0.219) [− 0.594 to 1]
AURA 339161.436.3I/II 10%
III 10%
IV 80%
0.808 (0.209) [−0.594 to 1]
AURA2/AURA3 combined59461.934.5I/II 10%
III 11%
IV 78%
0.799 (0.214 [−0.594 to 1]
Young et al. (2015)77168.344.1NR0.58 (0.342) [− 0.594 to 1]
Khan and Morris (2014)67077NRI/II 0%
III/IV 100%
0.61 (0.29) [−0.043 to 1]
Khan et al. (2016)986944I/II 27%
III 32%
IV 38%
0.515 (0.308) [−0.594 to 1]